Skip to main content
PMC home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 1993;91:653–699.

Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

T A Meredith 1
PMCID: PMC1298483  PMID: 8140706

Abstract

Ceftazidime has pharmacokinetic advantages for treatment of endophthalmitis caused by gram negative-organisms by intravenous administration. Additionally, its spectrum of coverage for these organisms and its relatively low toxicity after intraocular injection are favorable attributes. These studies demonstrate that inflammation leads to a significant reduction of the blood-ocular barriers to ceftazidime. This increased permeability shortens the half-life of the drug after intraocular injection but allows a significant penetration into the eye after a single intravenous dose so that therapeutic levels are achieved. Ceftazidime appears to be removed by both the anterior and the posterior route without active transport. The experiments demonstrate the importance of the vitreous as a barrier to achieving significant concentration of antibiotic within the eye after intravenous administration and confirm the importance of the vitreous in prolonging the half-life of drugs injected intravitreally. Finally the results emphasize that the pharmacokinetic behavior of drugs for treatment of endophthalmitis must be assessed in inflamed eyes both with and without intact vitreous, since these factors play a large role in drug availability and concentration in the vitreous cavity and are the major variables in the clinical setting.

Full text

PDF
655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alm A., Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macaca irus): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp Eye Res. 1973 Jan 1;15(1):15–29. doi: 10.1016/0014-4835(73)90185-1. [DOI] [PubMed] [Google Scholar]
  2. Axelrod J. L., Klein R. M., Bergen R. L., Sheikh M. Z. Human vitreous levels of selected antistaphylococcal antibiotics. Am J Ophthalmol. 1985 Oct 15;100(4):570–575. doi: 10.1016/0002-9394(85)90683-x. [DOI] [PubMed] [Google Scholar]
  3. Axelrod J. L., Kochman R. S., Horowitz M. A., Youngworth L. Ceftazidime concentrations in human aqueous humor. Arch Ophthalmol. 1984 Jun;102(6):923–925. doi: 10.1001/archopht.1984.01040030743035. [DOI] [PubMed] [Google Scholar]
  4. Axelrod J. L., Newton J. C., Klein R. M., Bergen R. L., Sheikh M. Z. Penetration of imipenem into human aqueous and vitreous humor. Am J Ophthalmol. 1987 Dec 15;104(6):649–653. doi: 10.1016/0002-9394(87)90180-2. [DOI] [PubMed] [Google Scholar]
  5. Barza M. Antibacterial agents in the treatment of ocular infections. Infect Dis Clin North Am. 1989 Sep;3(3):533–551. [PubMed] [Google Scholar]
  6. Barza M. Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation. Scand J Infect Dis Suppl. 1978;(14):151–159. [PubMed] [Google Scholar]
  7. Barza M., Kane A., Baum J. Comparison of the effects of continuous and intermittent systemic administration on the penetration of gentamicin into infected rabbit eyes. J Infect Dis. 1983 Jan;147(1):144–148. doi: 10.1093/infdis/147.1.144. [DOI] [PubMed] [Google Scholar]
  8. Barza M., Kane A., Baum J. Ocular penetration of subconjunctival oxacillin, methicillin, and cefazolin in rabbits with staphylococcal endophthalmitis. J Infect Dis. 1982 Jun;145(6):899–903. doi: 10.1093/infdis/145.6.899. [DOI] [PubMed] [Google Scholar]
  9. Barza M., Kane A., Baum J. Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in rhesus monkeys. Invest Ophthalmol Vis Sci. 1983 Dec;24(12):1602–1606. [PubMed] [Google Scholar]
  10. Barza M., Lynch E., Baum J. L. Pharmacokinetics of newer cephalosporins after subconjunctival and intravitreal injection in rabbits. Arch Ophthalmol. 1993 Jan;111(1):121–125. doi: 10.1001/archopht.1993.01090010125038. [DOI] [PubMed] [Google Scholar]
  11. Baum J., Peyman G. A., Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol. 1982 Jan-Feb;26(4):204–206. doi: 10.1016/0039-6257(82)90080-7. [DOI] [PubMed] [Google Scholar]
  12. Ben-Nun J., Joyce D. A., Cooper R. L., Cringle S. J., Constable I. J. Pharmacokinetics of intravitreal injection. Assessment of a gentamicin model by ocular dialysis. Invest Ophthalmol Vis Sci. 1989 Jun;30(6):1055–1061. [PubMed] [Google Scholar]
  13. Bill A. Blood circulation and fluid dynamics in the eye. Physiol Rev. 1975 Jul;55(3):383–417. doi: 10.1152/physrev.1975.55.3.383. [DOI] [PubMed] [Google Scholar]
  14. Bohigian G. M., Olk R. J. Factors associated with a poor visual result in endophthalmitis. Am J Ophthalmol. 1986 Mar 15;101(3):332–341. doi: 10.1016/0002-9394(86)90829-9. [DOI] [PubMed] [Google Scholar]
  15. Boldt H. C., Pulido J. S., Blodi C. F., Folk J. C., Weingeist T. A. Rural endophthalmitis. Ophthalmology. 1989 Dec;96(12):1722–1726. doi: 10.1016/s0161-6420(89)32658-3. [DOI] [PubMed] [Google Scholar]
  16. Campochiaro P. A., Conway B. P. Aminoglycoside toxicity--a survey of retinal specialists. Implications for ocular use. Arch Ophthalmol. 1991 Jul;109(7):946–950. doi: 10.1001/archopht.1991.01080070058035. [DOI] [PubMed] [Google Scholar]
  17. Campochiaro P. A., Green W. R. Toxicity of intravitreous ceftazidime in primate retina. Arch Ophthalmol. 1992 Nov;110(11):1625–1629. doi: 10.1001/archopht.1992.01080230125035. [DOI] [PubMed] [Google Scholar]
  18. Clements D. B., Tailor V. A study of aqueous and serum levels of ceftazidime following subconjunctival administration. Br J Ophthalmol. 1987 Jun;71(6):433–435. doi: 10.1136/bjo.71.6.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Cobo L. M., Forster R. K. The clearance of intravitreal gentamicin. Am J Ophthalmol. 1981 Jul;92(1):59–62. doi: 10.1016/s0002-9394(14)75908-2. [DOI] [PubMed] [Google Scholar]
  20. Conway B. P., Campochiaro P. A. Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. Arch Ophthalmol. 1986 Mar;104(3):367–371. doi: 10.1001/archopht.1986.01050150067028. [DOI] [PubMed] [Google Scholar]
  21. Conway B. P., Tabatabay C. A., Campochiaro P. A., D'Amico D. J., Hanninen L. A., Kenyon K. R. Gentamicin toxicity in the primate retina. Arch Ophthalmol. 1989 Jan;107(1):107–112. doi: 10.1001/archopht.1989.01070010109037. [DOI] [PubMed] [Google Scholar]
  22. D'Amico D. J., Caspers-Velu L., Libert J., Shanks E., Schrooyen M., Hanninen L. A., Kenyon K. R. Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol. 1985 Aug 15;100(2):264–275. doi: 10.1016/0002-9394(85)90792-5. [DOI] [PubMed] [Google Scholar]
  23. Davey P. G., Barza M., Stuart M. Dose response of experimental Pseudomonas endophthalmitis to ciprofloxacin, gentamicin, and imipenem: evidence for resistance to "late" treatment of infections. J Infect Dis. 1987 Mar;155(3):518–523. doi: 10.1093/infdis/155.3.518. [DOI] [PubMed] [Google Scholar]
  24. Davey R. T., Jr, Tauber W. B. Posttraumatic endophthalmitis: the emerging role of Bacillus cereus infection. Rev Infect Dis. 1987 Jan-Feb;9(1):110–123. doi: 10.1093/clinids/9.1.110. [DOI] [PubMed] [Google Scholar]
  25. Davis J. L., Koidou-Tsiligianni A., Pflugfelder S. C., Miller D., Flynn H. W., Jr, Forster R. K. Coagulase-negative staphylococcal endophthalmitis. Increase in antimicrobial resistance. Ophthalmology. 1988 Oct;95(10):1404–1410. doi: 10.1016/s0161-6420(88)32990-8. [DOI] [PubMed] [Google Scholar]
  26. Diamond J. G. Intraocular management of endophthalmitis. A systematic approach. Arch Ophthalmol. 1981 Jan;99(1):96–99. doi: 10.1001/archopht.1981.03930010098011. [DOI] [PubMed] [Google Scholar]
  27. Doft B. H. The endophthalmitis vitrectomy study. Arch Ophthalmol. 1991 Apr;109(4):487–489. doi: 10.1001/archopht.1991.01080040055025. [DOI] [PubMed] [Google Scholar]
  28. Doft B. H., Weiskopf J., Nilsson-Ehle I., Wingard L. B., Jr Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985 Nov;92(11):1601–1605. doi: 10.1016/s0161-6420(85)33838-1. [DOI] [PubMed] [Google Scholar]
  29. Donowitz G. R. Third generation cephalosporins. Infect Dis Clin North Am. 1989 Sep;3(3):595–612. [PubMed] [Google Scholar]
  30. Driebe W. T., Jr, Mandelbaum S., Forster R. K., Schwartz L. K., Culbertson W. W. Pseudophakic endophthalmitis. Diagnosis and management. Ophthalmology. 1986 Apr;93(4):442–448. doi: 10.1016/s0161-6420(86)33722-9. [DOI] [PubMed] [Google Scholar]
  31. Duguid J. P., Ginsberg M., Fraser I. C., Macaskill J., Michaelson I. C., Robson J. M. EXPERIMENTAL OBSERVATIONS ON THE INTRAVITREOUS USE OF PENICILLIN AND OTHER DRUGS. Br J Ophthalmol. 1947 Apr;31(4):193–211. [PMC free article] [PubMed] [Google Scholar]
  32. Ficker L., Meredith T. A., Gardner S., Wilson L. A. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest Ophthalmol Vis Sci. 1990 Mar 1;31(3):502–505. [PubMed] [Google Scholar]
  33. Fisher J. P., Civiletto S. E., Forster R. K. Toxicity, efficacy, and clearance of intravitreally injected of cefazolin. Arch Ophthalmol. 1982 Apr;100(4):650–652. doi: 10.1001/archopht.1982.01030030652026. [DOI] [PubMed] [Google Scholar]
  34. Flynn H. W., Jr, Pulido J. S., Pflugfelder S. C., Davis J. L., Culbertson W. W., Roussel T. J., Miller D. Endophthalmitis therapy: changing antibiotic sensitivity patterns and current therapeutic recommendations. Arch Ophthalmol. 1991 Feb;109(2):175–176. doi: 10.1001/archopht.1991.01080020021012. [DOI] [PubMed] [Google Scholar]
  35. Fox G. M., Joondeph B. C., Flynn H. W., Jr, Pflugfelder S. C., Roussel T. J. Delayed-onset pseudophakic endophthalmitis. Am J Ophthalmol. 1991 Feb 15;111(2):163–173. doi: 10.1016/s0002-9394(14)72254-8. [DOI] [PubMed] [Google Scholar]
  36. Gerber A. U., Craig W. A., Brugger H. P., Feller C., Vastola A. P., Brandel J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis. 1983 May;147(5):910–917. doi: 10.1093/infdis/147.5.910. [DOI] [PubMed] [Google Scholar]
  37. Irvine W. D., Flynn H. W., Jr, Miller D., Pflugfelder S. C. Endophthalmitis caused by gram-negative organisms. Arch Ophthalmol. 1992 Oct;110(10):1450–1454. doi: 10.1001/archopht.1992.01080220112031. [DOI] [PubMed] [Google Scholar]
  38. Jay W. M., Aziz M. Z., Rissing J. P., Shockley R. K. Pharmacokinetic analysis of intravitreal ceftriaxone in monkeys. Arch Ophthalmol. 1985 Jan;103(1):121–123. doi: 10.1001/archopht.1985.01050010127035. [DOI] [PubMed] [Google Scholar]
  39. Jay W. M., Fishman P., Aziz M., Shockley R. K. Intravitreal ceftazidime in a rabbit model: dose- and time-dependent toxicity and pharmacokinetic analysis. J Ocul Pharmacol. 1987 Fall;3(3):257–262. doi: 10.1089/jop.1987.3.257. [DOI] [PubMed] [Google Scholar]
  40. Jay W. M., Shockley R. K., Aziz A. M., Aziz M. Z., Rissing J. P. Ocular pharmacokinetics of ceftriaxone following subconjunctival injection in rabbits. Arch Ophthalmol. 1984 Mar;102(3):430–432. doi: 10.1001/archopht.1984.01040030344034. [DOI] [PubMed] [Google Scholar]
  41. Kasbeer R. T., Peyman G. A., May D. R., Homer P. I. Penetration of amikacin into the aphakic eye. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975 Aug 4;196(1):85–94. doi: 10.1007/BF00410030. [DOI] [PubMed] [Google Scholar]
  42. Keren G., Alhalel A., Bartov E., Kitzes-Cohen R., Rubinstein E., Segev S., Treister G. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2388–2392. [PubMed] [Google Scholar]
  43. Leopold I. H. Management of intra-ocular infection. Trans Ophthalmol Soc U K. 1971;91:577–610. [PubMed] [Google Scholar]
  44. Mann I. THE INTRA-OCULAR USE OF PENICILLIN. Br J Ophthalmol. 1946 Mar;30(3):134–146. [PMC free article] [PubMed] [Google Scholar]
  45. Mao L. K., Flynn H. W., Jr, Miller D., Pflugfelder S. C. Endophthalmitis caused by streptococcal species. Arch Ophthalmol. 1992 Jun;110(6):798–801. doi: 10.1001/archopht.1992.01080180070030. [DOI] [PubMed] [Google Scholar]
  46. Marmor M. F. Retinal detachment from hyperosmotic intravitreal injection. Invest Ophthalmol Vis Sci. 1979 Dec;18(12):1237–1244. [PubMed] [Google Scholar]
  47. Martin D. F., Ficker L. A., Aguilar H. A., Gardner S. K., Wilson L. A., Meredith T. A. Vitreous cefazolin levels after intravenous injection. Effects of inflammation, repeated antibiotic doses, and surgery. Arch Ophthalmol. 1990 Mar;108(3):411–414. doi: 10.1001/archopht.1990.01070050109043. [DOI] [PubMed] [Google Scholar]
  48. Meredith T. A., Lindsey D. T., Edelhauser H. F., Goldman A. I. Electroretinographic studies following vitrectomy and intraocular silicone oil injection. Br J Ophthalmol. 1985 Apr;69(4):254–260. doi: 10.1136/bjo.69.4.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Nelsen P., Peyman G. A., Bennett T. O. BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis. Am J Ophthalmol. 1974 Jul;78(1):82–89. doi: 10.1016/0002-9394(74)90013-0. [DOI] [PubMed] [Google Scholar]
  50. Norrby S. R. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Am J Med. 1985 Aug 9;79(2A):56–61. doi: 10.1016/0002-9343(85)90262-1. [DOI] [PubMed] [Google Scholar]
  51. Novack G. D., Leopold I. H. The blood-aqueous and blood-brain barriers to permeability. Am J Ophthalmol. 1988 Apr 15;105(4):412–416. doi: 10.1016/0002-9394(88)90308-x. [DOI] [PubMed] [Google Scholar]
  52. O'Day D. M., Smith R. S., Gregg C. R., Turnbull P. C., Head W. S., Ives J. A., Ho P. C. The problem of bacillus species infection with special emphasis on the virulence of Bacillus cereus. Ophthalmology. 1981 Aug;88(8):833–838. doi: 10.1016/s0161-6420(81)34960-4. [DOI] [PubMed] [Google Scholar]
  53. Olson J. C., Flynn H. W., Jr, Forster R. K., Culbertson W. W. Results in the treatment of postoperative endophthalmitis. Ophthalmology. 1983 Jun;90(6):692–699. doi: 10.1016/s0161-6420(83)34511-5. [DOI] [PubMed] [Google Scholar]
  54. Oum B. S., D'Amico D. J., Wong K. W. Intravitreal antibiotic therapy with vancomycin and aminoglycoside. An experimental study of combination and repetitive injections. Arch Ophthalmol. 1989 Jul;107(7):1055–1060. doi: 10.1001/archopht.1989.01070020117043. [DOI] [PubMed] [Google Scholar]
  55. Pavan P. R., Brinser J. H. Exogenous bacterial endophthalmitis treated without systemic antibiotics. Am J Ophthalmol. 1987 Aug 15;104(2):121–126. doi: 10.1016/0002-9394(87)90002-x. [DOI] [PubMed] [Google Scholar]
  56. Peyman G. A. Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections. Surv Ophthalmol. 1977 Jan-Feb;21(4):332, 339-46. [PubMed] [Google Scholar]
  57. Peyman G. A., Herbst R. Bacterial endophthalmitis. Treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol. 1974 May;91(5):416–418. doi: 10.1001/archopht.1974.03900060428017. [DOI] [PubMed] [Google Scholar]
  58. Peyman G. A., Nelsen P., Bennett T. O. Intravitreal injection of kanamycin in experimentally induced endophthalmitis. Can J Ophthalmol. 1974 Jul;9(3):322–327. [PubMed] [Google Scholar]
  59. Peyman G. A., Vastine D. W., Raichand M. Experimental aspects and their clinical application. Ophthalmology. 1978 Apr;85(4):374–385. doi: 10.1016/s0161-6420(78)35659-1. [DOI] [PubMed] [Google Scholar]
  60. Pflugfelder S. C., Hernández E., Fliesler S. J., Alvarez J., Pflugfelder M. E., Forster R. K. Intravitreal vancomycin. Retinal toxicity, clearance, and interaction with gentamicin. Arch Ophthalmol. 1987 Jun;105(6):831–837. doi: 10.1001/archopht.1987.01060060117045. [DOI] [PubMed] [Google Scholar]
  61. Quagliarello V., Scheld W. M. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med. 1992 Sep 17;327(12):864–872. doi: 10.1056/NEJM199209173271208. [DOI] [PubMed] [Google Scholar]
  62. Rubinstein E., Goldfarb J., Keren G., Blumenthal M., Treister G. The penetration of gentamicin into the vitreous humor in man. Invest Ophthalmol Vis Sci. 1983 May;24(5):637–639. [PubMed] [Google Scholar]
  63. Rubinstein E., Triester G., Avni I., Schwartzkopf R. The intravitreal penetration of cefotaxime in man following systemic and subconjunctival administrations. Ophthalmology. 1987 Jan;94(1):30–34. doi: 10.1016/s0161-6420(87)33506-7. [DOI] [PubMed] [Google Scholar]
  64. Scheld W. M., Sande M. A. Bactericidal versus bacteriostatic antibiotic therapy of experimental pneumococcal meningitis in rabbits. J Clin Invest. 1983 Mar;71(3):411–419. doi: 10.1172/JCI110785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Schenk A. G., Peyman G. A., Paque J. T. The intravitreal use of carbenicillin (Geopen) for treatment od pseudomonas endophthalmitis. Acta Ophthalmol (Copenh) 1974;52(5):707–717. doi: 10.1111/j.1755-3768.1974.tb01105.x. [DOI] [PubMed] [Google Scholar]
  66. Shockley R. K., Fishman P., Aziz M., Yannis R. A., Jay W. M. Subconjunctival administration of ceftazidime in pigmented rabbit eyes. Arch Ophthalmol. 1986 Feb;104(2):266–268. doi: 10.1001/archopht.1986.01050140124033. [DOI] [PubMed] [Google Scholar]
  67. Shockley R. K., Jay W. M., Friberg T. R., Aziz A. M., Rissing J. P., Aziz M. Z. Intravitreal ceftriaxone in a rabbit model. Dose- and time-dependent toxic effects and pharmacokinetic analysis. Arch Ophthalmol. 1984 Aug;102(8):1236–1238. doi: 10.1001/archopht.1984.01040031006037. [DOI] [PubMed] [Google Scholar]
  68. Smith M. A., Sorenson J. A., Lowy F. D., Shakin J. L., Harrison W., Jakobiec F. A. Treatment of experimental methicillin-resistant Staphylococcus epidermidis endophthalmitis with intravitreal vancomycin. Ophthalmology. 1986 Oct;93(10):1328–1335. doi: 10.1016/s0161-6420(86)33579-6. [DOI] [PubMed] [Google Scholar]
  69. Spivey J. M. The postantibiotic effect. Clin Pharm. 1992 Oct;11(10):865–875. [PubMed] [Google Scholar]
  70. Stern G. A., Engel H. M., Driebe W. T., Jr Recurrent postoperative endophthalmitis. Cornea. 1990 Apr;9(2):102–107. [PubMed] [Google Scholar]
  71. Streilein J. W. Anterior chamber associated immune deviation: the privilege of immunity in the eye. Surv Ophthalmol. 1990 Jul-Aug;35(1):67–73. doi: 10.1016/0039-6257(90)90048-z. [DOI] [PubMed] [Google Scholar]
  72. Streilein J. W., Wilbanks G. A., Cousins S. W. Immunoregulatory mechanisms of the eye. J Neuroimmunol. 1992 Aug;39(3):185–200. doi: 10.1016/0165-5728(92)90253-h. [DOI] [PubMed] [Google Scholar]
  73. Talamo J. H., D'Amico D. J., Hanninen L. A., Kenyon K. R., Shanks E. T. The influence of aphakia and vitrectomy on experimental retinal toxicity of aminoglycoside antibiotics. Am J Ophthalmol. 1985 Dec 15;100(6):840–847. doi: 10.1016/s0002-9394(14)73377-x. [DOI] [PubMed] [Google Scholar]
  74. Talamo J. H., D'Amico D. J., Kenyon K. R. Intravitreal amikacin in the treatment of bacterial endophthalmitis. Arch Ophthalmol. 1986 Oct;104(10):1483–1485. doi: 10.1001/archopht.1986.01050220077030. [DOI] [PubMed] [Google Scholar]
  75. Tanabe J., Kitano K., Suzuki T., Okayama Y., Mochizuki K., Kawasaki K. Nontoxic concentration of ceftazidime and flomoxef sodium for intravitreal use--evaluated by in-vitro ERG. Lens Eye Toxic Res. 1990;7(3-4):677–683. [PubMed] [Google Scholar]
  76. Thea D., Barza M. Use of antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am. 1989 Sep;3(3):553–570. [PubMed] [Google Scholar]
  77. Täuber M. G., Doroshow C. A., Hackbarth C. J., Rusnak M. G., Drake T. A., Sande M. A. Antibacterial activity of beta-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J Infect Dis. 1984 Apr;149(4):568–574. doi: 10.1093/infdis/149.4.568. [DOI] [PubMed] [Google Scholar]
  78. Täuber M. G., Sande M. A. General principles of therapy of pyogenic meningitis. Infect Dis Clin North Am. 1990 Dec;4(4):661–676. [PubMed] [Google Scholar]
  79. Vogelman B., Craig W. A. Kinetics of antimicrobial activity. J Pediatr. 1986 May;108(5 Pt 2):835–840. doi: 10.1016/s0022-3476(86)80754-5. [DOI] [PubMed] [Google Scholar]
  80. Walstad R. A., Blika S. Penetration of ceftazidime into the normal rabbit and human eye. Scand J Infect Dis Suppl. 1985;44:63–67. [PubMed] [Google Scholar]
  81. Walstad R. A., Blika S., Thurmann-Nielsen E., Halvorsen T. B. The penetration of ceftazidime into the inflamed rabbit eye. Scand J Infect Dis. 1987;19(1):131–135. doi: 10.3109/00365548709032388. [DOI] [PubMed] [Google Scholar]
  82. Walstad R. A., Hellum K. B., Blika S., Dale L. G., Fredriksen T., Myhre K. I., Spencer G. R. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):275–282. doi: 10.1093/jac/12.suppl_a.275. [DOI] [PubMed] [Google Scholar]
  83. Yannis R. A., Rissing J. P., Buxton T. B., Shockley R. K. Multistrain comparison of three antimicrobial prophylaxis regimens in experimental postoperative Pseudomonas endophthalmitis. Am J Ophthalmol. 1985 Sep 15;100(3):404–407. doi: 10.1016/0002-9394(85)90501-x. [DOI] [PubMed] [Google Scholar]
  84. Yoshizumi M. O., Leinwand M. J., Kim J. Topical and intravenous gentamicin in traumatically lacerated eyes. Graefes Arch Clin Exp Ophthalmol. 1992;230(2):175–177. doi: 10.1007/BF00164659. [DOI] [PubMed] [Google Scholar]
  85. Zachary I. G., Forster R. K. Experimental intravitreal gentamicin. Am J Ophthalmol. 1976 Oct;82(4):604–611. doi: 10.1016/0002-9394(76)90549-3. [DOI] [PubMed] [Google Scholar]
  86. Zhanel G. G., Hoban D. J., Harding G. K. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991 Feb;25(2):153–163. doi: 10.1177/106002809102500210. [DOI] [PubMed] [Google Scholar]
  87. el Baba F. Z., Trousdale M. D., Gauderman W. J., Wagner D. G., Liggett P. E. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology. 1992 Apr;99(4):483–486. doi: 10.1016/s0161-6420(92)31943-8. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES